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接触发挥调节作用，而 CD4+IL-10+IL-4- T 细胞(Tr1)主要通过分泌抑制性细胞因
子 IL-10 发挥作用。本文首次在小鼠同种异体心脏移植模型中，研究通过体内诱
导上述两种调节性 T 细胞来维持移植物长期免疫耐受的方法和机制。 




分析调节性 T 细胞亚群 CD4+CD25+Foxp3+Treg 和 CD4+CD25-IL-10+IL-4-Tr1 分别
在免疫耐受中的调节机制。 
结果：在初次心脏移植模型中，我们发现，单独使用雷帕霉素仅有约 50%
小鼠可以长期存活，而联合应用雷帕霉素和重组细胞因子 IL-10 可以诱导 100%
的小鼠心脏移植的免疫耐受（>100 天）。在移植术后 6 天、30 天、100 天进行检
测，H&E 结果显示，联合用药组较其他组炎性破坏明显降低。ELISA 检测发现，




































结论：雷帕霉素和重组细胞因子 IL-10 联合给药可以诱导 CD4+Foxp3+Treg






















Background:In most experimental model of transplantation, the heart and lung 
allograft are called ―tolerance resistant‖ organs (compared with the ―tolerance prone‖ 
organs). It’s reported the one-year survival of heart transplantation have been 
obviously improved from the 2000s, but long-term tolerance is still a major challenge. 
The abuse of immunosuppressive drugs, the side-effects of these chronic medicines 
and the absence of methods to reach a donor-specific tolerance state are the obstacles 
to prolong the heart transplantation survival. Regulatory T cell therapy has generally 
been used for autoimmune diseases and is less frequently applied for transplantation 





Tregs and T regulatory type 1 (Tr1) cells in vivo to maintain 
long-term tolerance after heart transplantation.  
Methods: C57BL/6 mice were transplanted with hearts from BALB/c mice. We 











 day after transplantation, the 
levels of rejection were analyzed by hematoxylin & eosin staining, ELISA and q-PCR, 
cell subtype was identified by flow cytometry, and the second immuno-response to the 
alloantigens was detected by MLR. 
Results: Combined treatment with (hu) IL-10 and rapamycin could induce 
tolerance to the heart allograft in all recipient mice, and levels of IL-2 and INF-γ were 
also clearly decreased in the tolerance group. And compared with the Rapa group, the 





Tregs induced by this treatment keep high during the administration 
period and recovered to normal levels on the 100
th
 day after transplantation, yet the 
proportion of Tr1 cells remained high after drug withdrawal. Mixed lymphocyte 
reactions showed that the recipient's T cells were tolerant (showed no response) to the 
donor’s APCs rather than the third-party donor’s APCs. 




















Tregs and Tr1 cells in vivo. The two subsets showed different regulatory 
effects in the mouse model of heart transplantation and could maintain a low immune 
response environment to facilitate long-term graft survival. This combination provides 
a promising treatment for clinical heart transplantation. 
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图 1.1 移植后死亡原因随移植后时间的变化[1] 
Fig1.1 Contribution of leading causes of death to mortality by time since adult 










表 1.1 器官移植进行免疫抑制的方法 


























噬作用、以及 IL-1 的分泌降低淋巴细胞功能，此外，还可以通过阻断 Th 细胞中
IL-2 的分泌抑制杀伤性 T 细胞的活性[3]；虽然皮质类激素对 B 细胞没有直接的抑




10-20mg/kg,移植后用量逐渐，三个月之内由 1-2 mg/kg/day 降低至 0.31-2 
mg/kg/day，接下来以 0.15-0.21 mg/kg/day 进行维持治疗。对于急性排斥的治疗：
500-10001mg/kg/day 大剂量静脉注射 2-3 天，然后以每三天降低 50%的剂量用药。 
（2）抗代谢药 
咪唑硫嘌呤（Az）直至 1980 年咪唑硫嘌呤联合皮质激素作为免疫抑制方案
应用于临床肾移植持续了 15 年之久。咪唑硫嘌呤作用于细胞周期 S 期，抑制核




唑硫嘌呤的合适剂量如下：移植后 60 天内用药剂量为 2.45mg/kg/day，60-91 天
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